Emtricitabine; Tenofovir Disoproxil Fumarate Patent Expiration
Emtricitabine; Tenofovir Disoproxil Fumarate is Used for treating HIV-1 infection in adults and pediatric patients. It was first introduced by Gilead Sciences Inc
Emtricitabine; Tenofovir Disoproxil Fumarate Patents
Given below is the list of patents protecting Emtricitabine; Tenofovir Disoproxil Fumarate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Truvada | US5814639 | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep 29, 2015
(Expired) | Gilead |
| Truvada | US5814639 | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep 29, 2015
(Expired) | Gilead |
| Truvada |
US5814639 (Pediatric) | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar 29, 2016
(Expired) | Gilead |
| Truvada | US5914331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul 02, 2017
(Expired) | Gilead |
| Truvada | US5914331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul 02, 2017
(Expired) | Gilead |
| Truvada |
US5914331 (Pediatric) | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan 02, 2018
(Expired) | Gilead |
| Truvada | US5922695 | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul 25, 2017
(Expired) | Gilead |
| Truvada | US5922695 | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul 25, 2017
(Expired) | Gilead |
| Truvada |
US5922695 (Pediatric) | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan 25, 2018
(Expired) | Gilead |
| Truvada | US5935946 | Nucleotide analog composition and synthesis method |
Jul 25, 2017
(Expired) | Gilead |
| Truvada | US5935946 | Nucleotide analog composition and synthesis method |
Jul 25, 2017
(Expired) | Gilead |
| Truvada |
US5935946 (Pediatric) | Nucleotide analog composition and synthesis method |
Jan 25, 2018
(Expired) | Gilead |
| Truvada | US5977089 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul 25, 2017
(Expired) | Gilead |
| Truvada | US5977089 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul 25, 2017
(Expired) | Gilead |
| Truvada |
US5977089 (Pediatric) | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan 25, 2018
(Expired) | Gilead |
| Truvada | US6043230 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul 25, 2017
(Expired) | Gilead |
| Truvada |
US6043230 (Pediatric) | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan 25, 2018
(Expired) | Gilead |
| Truvada | US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov 04, 2020
(Expired) | Gilead |
| Truvada |
US6642245 (Pediatric) | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May 04, 2021
(Expired) | Gilead |
| Truvada | US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar 09, 2021
(Expired) | Gilead |
| Truvada | US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar 09, 2021
(Expired) | Gilead |
| Truvada |
US6703396 (Pediatric) | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep 09, 2021
(Expired) | Gilead |
| Truvada | US8592397 | Compositions and methods for combination antiviral therapy |
Jan 13, 2024
(Expired) | Gilead |
| Truvada | US8716264 | Compositions and methods for combination antiviral therapy |
Jan 13, 2024
(Expired) | Gilead |
| Truvada |
US8716264 (Pediatric) | Compositions and methods for combination antiviral therapy |
Jul 13, 2024
(Expired) | Gilead |
| Truvada | US9457036 | Compositions and methods for combination antiviral therapy |
Jan 13, 2024
(Expired) | Gilead |
| Truvada | US9744181 | Compositions and methods for combination antiviral therapy |
Jan 13, 2024
(Expired) | Gilead |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Emtricitabine; Tenofovir Disoproxil Fumarate Generics
Several generic applications have been filed for Emtricitabine; Tenofovir Disoproxil Fumarate. The first generic version for Emtricitabine; Tenofovir Disoproxil Fumarate was by Teva Pharmaceuticals Usa Inc and was approved on Jun 8, 2017. And the latest generic version is by Aurobindo Pharma Ltd and was approved on Mar 9, 2023.
Given below is the list of companies who have filed for Emtricitabine; Tenofovir Disoproxil Fumarate generic.
1. MYLAN
Mylan Pharmaceuticals Inc has filed for 1 generic for Emtricitabine; Tenofovir Disoproxil Fumarate. This 200mg;300mg version comes by the name EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG; 300MG | tablet | Prescription | ORAL | AB | Apr 9, 2018 |
2. CIPLA
Cipla Ltd has filed for 1 generic for Emtricitabine; Tenofovir Disoproxil Fumarate. This 200mg;300mg version comes by the name EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE. Given below are the details of the strengths of this generic introduced by Cipla.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG; 300MG | tablet | Discontinued | ORAL | N/A | Apr 2, 2021 |
3. TEVA PHARMS USA
Teva Pharmaceuticals Usa Inc has filed for 1 generic for Emtricitabine; Tenofovir Disoproxil Fumarate. This 200mg;300mg version comes by the name EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG; 300MG | tablet | Prescription | ORAL | AB | Jun 8, 2017 |
4. CHARTWELL RX
Chartwell Rx Sciences Llc has filed for 1 generic for Emtricitabine; Tenofovir Disoproxil Fumarate. This 200mg;300mg version comes by the name EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE. Given below are the details of the strengths of this generic introduced by Chartwell Rx.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG; 300MG | tablet | Prescription | ORAL | AB | Jun 4, 2021 |
5. HETERO LABS LTD III
Hetero Labs Ltd Unit Iii has filed for 1 generic for Emtricitabine; Tenofovir Disoproxil Fumarate. This 200mg;300mg version comes by the name EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd Iii.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG; 300MG | tablet | Prescription | ORAL | AB | Oct 7, 2021 |
6. AUROBINDO PHARMA LTD
Aurobindo Pharma Ltd has filed for 3 different strengths of generic version for Emtricitabine; Tenofovir Disoproxil Fumarate. All of these versions come by the name EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 133MG; 200MG | tablet | Prescription | ORAL | AB | Mar 9, 2023 |
| 100MG; 150MG | tablet | Prescription | ORAL | AB | Mar 9, 2023 |
| 167MG; 250MG | tablet | Prescription | ORAL | AB | Mar 9, 2023 |
7. STRIDES PHARMA
Strides Pharma Global Pte Ltd has filed for 1 generic for Emtricitabine; Tenofovir Disoproxil Fumarate. This 200mg;300mg version comes by the name EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE. Given below are the details of the strengths of this generic introduced by Strides Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG; 300MG | tablet | Prescription | ORAL | AB | Jan 13, 2021 |
8. LAURUS
Laurus Labs Ltd has filed for 1 generic for Emtricitabine; Tenofovir Disoproxil Fumarate. This 200mg;300mg version comes by the name EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE. Given below are the details of the strengths of this generic introduced by Laurus.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG; 300MG | tablet | Prescription | ORAL | AB | Jul 26, 2019 |
9. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 4 different strengths of generic version for Emtricitabine; Tenofovir Disoproxil Fumarate. All of these versions come by the name EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG; 300MG | tablet | Prescription | ORAL | AB | Feb 28, 2020 |
| 100MG; 150MG | tablet | Prescription | ORAL | AB | Jul 1, 2021 |
| 167MG; 250MG | tablet | Prescription | ORAL | AB | Jul 1, 2021 |
| 133MG; 200MG | tablet | Prescription | ORAL | AB | Jul 1, 2021 |
10. AUROBINDO PHARMA
Aurobindo Pharma Ltd has filed for 1 generic for Emtricitabine; Tenofovir Disoproxil Fumarate. This 200mg;300mg version comes by the name EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG; 300MG | tablet | Prescription | ORAL | AB | Jan 26, 2018 |
11. MACLEODS PHARMS LTD
Macleods Pharmaceuticals Ltd has filed for 1 generic for Emtricitabine; Tenofovir Disoproxil Fumarate. This 200mg;300mg version comes by the name EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE. Given below are the details of the strengths of this generic introduced by Macleods Pharms Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG; 300MG | tablet | Prescription | ORAL | AB | May 15, 2020 |
12. APOTEX
Apotex Inc has filed for 1 generic for Emtricitabine; Tenofovir Disoproxil Fumarate. This 200mg;300mg version comes by the name EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG; 300MG | tablet | Discontinued | ORAL | N/A | Jun 16, 2021 |
13. AMNEAL PHARMS CO
Amneal Pharmaceuticals Co Gmbh has filed for 4 different strengths of generic version for Emtricitabine; Tenofovir Disoproxil Fumarate. All of these versions come by the name EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE. Given below are the details of the strengths of this generic introduced by Amneal Pharms Co.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG; 300MG | tablet | Prescription | ORAL | AB | Aug 22, 2018 |
| 167MG; 250MG | tablet | Prescription | ORAL | AB | Aug 22, 2018 |
| 133MG; 200MG | tablet | Prescription | ORAL | AB | Aug 22, 2018 |
| 100MG; 150MG | tablet | Prescription | ORAL | AB | Aug 22, 2018 |